Clinical trial
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic…
NCT00003181 · Hope Cancer Institute, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00003181 |
|---|---|
| Title | Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Study Using Low Dose Subcutaneous IL-2, Vinblastine and GM-CSF in the Treatment of Metastatic Renal Cell Carcinoma |
| Lead sponsor | Hope Cancer Institute, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, sargramostim, vinblastine sulfate |
| Enrollment | 35 |
| Start date | May 1, 1997 |
| First posted | Apr 30, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: